These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1364 related articles for article (PubMed ID: 20615965)

  • 1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
    Chang BY; Huang MM; Francesco M; Chen J; Sokolove J; Magadala P; Robinson WH; Buggy JJ
    Arthritis Res Ther; 2011 Jul; 13(4):R115. PubMed ID: 21752263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
    J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
    Aalipour A; Advani RH
    Br J Haematol; 2013 Nov; 163(4):436-43. PubMed ID: 24111579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Roskoski R
    Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
    Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
    Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
    Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
    Kil LP; de Bruijn MJ; van Nimwegen M; Corneth OB; van Hamburg JP; Dingjan GM; Thaiss F; Rimmelzwaan GF; Elewaut D; Delsing D; van Loo PF; Hendriks RW
    Blood; 2012 Apr; 119(16):3744-56. PubMed ID: 22383797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib and novel BTK inhibitors in clinical development.
    Akinleye A; Chen Y; Mukhi N; Song Y; Liu D
    J Hematol Oncol; 2013 Aug; 6():59. PubMed ID: 23958373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.
    Shinohara M; Chang BY; Buggy JJ; Nagai Y; Kodama T; Asahara H; Takayanagi H
    Bone; 2014 Mar; 60():8-15. PubMed ID: 24316417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
    Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
    J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.
    Hutcheson J; Vanarsa K; Bashmakov A; Grewal S; Sajitharan D; Chang BY; Buggy JJ; Zhou XJ; Du Y; Satterthwaite AB; Mohan C
    Arthritis Res Ther; 2012 Nov; 14(6):R243. PubMed ID: 23136880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
    Evans EK; Tester R; Aslanian S; Karp R; Sheets M; Labenski MT; Witowski SR; Lounsbury H; Chaturvedi P; Mazdiyasni H; Zhu Z; Nacht M; Freed MI; Petter RC; Dubrovskiy A; Singh J; Westlin WF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):219-28. PubMed ID: 23709115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New roles for B cell receptor associated kinases: when the B cell is not the target.
    Nguyen PH; Niesen E; Hallek M
    Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
    Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
    J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.